Abstracts Archive - Page 618 of 2607 - ACR Meeting Abstracts

Abstract Number: 2025 • ACR Convergence 2022
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Brandon Law¹, Margaret Beach², Eileen Pelayo², Ilias Alevizos², Zohreh Khavandgar², Blake Warner² and Alan Baer¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
Abstract Number: 2033 • ACR Convergence 2022
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 2039 • ACR Convergence 2022
The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome
Sarah Pringle¹, Floris Bikker², Wouter Vogel³, Ingrid Hofland³, Bert van der Vegt⁴, Hendrika Bootsma¹, Frans Kroese¹, Arjan Vissink⁵ and Matthijs Valstar³, ¹University Medical Center Groningen, Groningen, Netherlands, ²ACTA, Amsterdam, Netherlands, ³NKI, Amsterdam, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵UMCG, Leek, Netherlands
Background/Purpose: Primary Sjögren's syndrome (pSS) often results in dysfunction of the salivary glands (hyposalivation and xerostomia) and substantial decrease in patient quality of life. High…
Abstract Number: 2031 • ACR Convergence 2022
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Dong Xu¹, Shangzhu Zhang¹, Cibo Huang², Chenghui Huang³, Li Qin⁴, Xiaomei Li⁵, Meiqing Chen⁶, Xiumei Liu⁷, Yi Liu⁸, Zhijun Li⁹, Jiankang Hu¹⁰, Chunde Bao¹¹, wei Wei¹², Jing Tian¹³, Xinwang Duan¹⁴, Jianmin Fang¹⁵ and Xiaofeng Zeng¹⁶, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Beijing Hospital, Beijing, China, ³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁴Huzhou Third Municipal Hospital, Huzhou, China, ⁵Anhui Provincial Hospital, Hefei, China, ⁶The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁷The First Hospital of Shanxi Medical University, Taiyuan, China, ⁸West China Hospital of Sichuan University, Chengdu, China, ⁹The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁰Jiangxi Pingxiang People’s Hospital, Shanghai, China, ¹¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ¹²Tianjin Medical University General Hospital, Tianjin, China, ¹³Second Xiangya Hospital of Central South University, Changsha, China, ¹⁴The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁵Shanghai Tongji Hospital, Shanghai, China, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
Abstract Number: 2027 • ACR Convergence 2022
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Uzma Nakshbandi¹, Martha S. van Ginkel¹, Silvia Liefers², Hendrika Bootsma², Fred Spijkervet², Arjan Vissink¹, Bert van der Vegt¹ and Frans Kroese², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
Abstract Number: 2038 • ACR Convergence 2022
Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome
Sarah Pringle¹, Fred Spijkervet¹, Arjan Vissink², Hendrika Bootsma¹ and Frans Kroese¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²UMCG, Leek, Netherlands
Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…
Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
Abstract Number: 2042 • ACR Convergence 2022
Sjögren’s Disease and Mitochondrial Function
Biji T Kurien¹, Pharaoh Gavin², Joshua Cavett¹, Valerie Lewis³, Ambre Chambers¹, Bhaskaran Shylesh⁴, Anjum Juvaria¹, Brittany Karfonta¹, Lida Radfar¹, Astrid Rasmussen⁴, Christopher Lessard⁴, Darise Farris⁴, Kathy Sivils⁵, Kristi A Koelsch⁴, Holly Van Remmen⁴ and R. Hal Scofield¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Washington, Seattle, WA, ³Veterans Affairs Medical Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Sjögren's disease (SjD) is a chronic inflammatory, autoimmune disorder with reduced lacrimal/salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia, respectively. Also, SjD patients…
Abstract Number: 2041 • ACR Convergence 2022
Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome
SABA NAYAR¹, Jason D. turner¹, Saba Asam¹, Charlotte G. Smith¹, Serena Colfrancesco², Ana Teodósio¹, Joe Flint¹, David H Gardner¹, Professor Simon Bowman³, Adam Croft¹, Andrew Filer¹, Benjamin A. Fisher¹, Christopher Buckley⁴ and Francesca Barone⁵, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Rome, Rome, Italy, ³University Hospitals Birmingham, Birmingham, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵University of Birmingham, Needham, MA
Background/Purpose: Sjögren's syndrome (SjS) shares a series of symptoms with non-SjS Sicca syndrome, a salivary gland disease characterised by glandular dysfunction and dryness. However, unlike…
Abstract Number: 2043 • ACR Convergence 2022
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
Eléonore Bettacchioli¹, Alain Saraux², Alice Tison³, Divi CORNEC⁴, Maryvonne Dueymes¹, Marta Alarcon-Riquelme⁵ and Valerie Devauchelle⁶, ¹Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, ²CHU Brest, Brest, France, ³Rheumatology Department, CHRU Brest, Brest, France, ⁴CHRU Brest, Brest, France, ⁵Center for Genomics and Oncological Research (GENYO), Granada, Spain, ⁶Université de Bretagne Occidentale, Brest, France
Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…
Abstract Number: 2047 • ACR Convergence 2022
Discriminative Power of Salivary Gland Ultrasound in Relation to Symptom-based Endotypes in Suspected and Definite Primary Sjögren’s Syndrome
Liselotte Deroo¹, Helena Achten², Eva Genbrugge², Wouter Bauters², Dimitri Roels², Frederick Dochy², David Creytens², Ann-Sophie Kathleen De Craemer², Filip Van den bosch³, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁴Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁵Ghent University Hospital, Ghent, Belgium
Background/Purpose: Primary Sjögren's Syndrome (pSS) is characterized by xerophthalmia, xerostomia and increased lymphoma risk. To address heterogeneity in symptoms, Tarn et al. applied cluster analysis…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
Abstract Number: 2044 • ACR Convergence 2022
Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
Elodie Riviere¹, Juliette Pascaud¹, Franck Letourneur², Gaetane Nocturne³ and Xavier Mariette⁴, ¹Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ²Genomic, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ³APHP, Le Kremlin Bicêtre, France, ⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France
Background/Purpose: Salivary gland epithelial cells (SGECs) are not only the target of autoimmunity in primary Sjögren's syndrome (pSS). SGECs may interact with lymphocytes and therefore…
Abstract Number: 2045 • ACR Convergence 2022
Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Maxime Beydon¹, Marie Dulin², Raphaèle Seror³, Frederic Desmoulins², Xavier Mariette⁴ and Gaetane Nocturne⁵, ¹Université Paris Cité, Paris, France, ²Kremlin Bicêtre Hospital - APHP, Paris, France, ³University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁵APHP, Le Kremlin Bicêtre, France
Background/Purpose: It is well established that in systemic lupus erythematous (SLE), disease burden is higher in patients from African ancestry (AA) than in Caucasian patients.…
Abstract Number: 1885 • ACR Convergence 2022
Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
Noemie Le Gouellec¹, Louai Zaidan², Eric Hachulla³, Nicolas Dognon³, Robin Dhote⁴, Sebastien Riviere⁵, Yurdagul Uzunhan⁴, Luc Mouthon⁶ and Jerome Authier⁷, ¹CH Valenciennes, Valenciennes, France, ²CHU Henri Mondor, Creteil, France, ³University of Lille, LILLE, France, ⁴Hopital Avicenne - Paris University, Bobigny, France, ⁵Hopital Saint Antoine - Paris University, Paris, France, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Paris Est - Creteil University, Creteil, France
Background/Purpose: Muscle involvement in systemic sclerosis (SSc) has been shown to be heterogeneous. Histopathological pattern seems to be associated with prognosis, but studies evaluating the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].